IC
Ikarian Capital Portfolio holdings
AUM
$302M
1-Year Return
65.21%
This Quarter Return
+3.95%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$672M
AUM Growth
+$124M
(+23%)
Cap. Flow
+$84.6M
Cap. Flow
% of AUM
12.6%
Top 10 Holdings %
Top 10 Hldgs %
24.63%
Holding
266
New
64
Increased
38
Reduced
42
Closed
20
Top Buys
| 1 |
Eli Lilly
LLY
|
$23.4M |
| 2 |
MacroGenics
MGNX
|
$15.9M |
| 3 |
Galapagos
GLPG
|
$15.5M |
| 4 |
X4 Pharmaceuticals
XFOR
|
$15.4M |
| 5 |
Relmada Therapeutics
RLMD
|
$10.2M |
Top Sells
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$29.5M |
| 2 |
KalVista Pharmaceuticals
KALV
|
$19.7M |
| 3 |
Prothena Corp
PRTA
|
$18.8M |
| 4 |
Bristol-Myers Squibb
BMY
|
$17.9M |
| 5 |
Celldex Therapeutics
CLDX
|
$15.8M |
Sector Composition
| 1 | Healthcare | 98.54% |
| 2 | Consumer Staples | 0.23% |
| 3 | Financials | 0.12% |
| 4 | Industrials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SRRA
26
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $7.67M | 0.26% |
445,188
+126,298
| +40% | +$2.18M |
|
|
27
KalVista Pharmaceuticals
KALV
$766M
| $7.63M | 0.26% |
296,965
-766,996
| -72% | -$19.7M |
|
28
Seres Therapeutics
MCRB
$165M
| $7.21M | 0.24% |
+17,500
| New | +$7.21M |
|
|
AUTL
29
Autolus Therapeutics
AUTL
$383M
| $7.2M | 0.24% |
+1,256,048
| New | +$7.2M |
|
30
Ocular Therapeutix
OCUL
$2.2B
| $6.89M | 0.23% |
419,573
-265,000
| -39% | -$4.35M |
|
|
SAGE
31
DELISTED
Sage Therapeutics
SAGE
| $6.82M | 0.23% |
91,151
+25,000
| +38% | +$1.87M |
|
32
Ardelyx
ARDX
$1.57B
| $6.82M | 0.23% |
1,030,436
-125,000
| -11% | -$827K |
|
33
Verastem
VSTM
$630M
| $6.66M | 0.22% |
224,533
+36,650
| +20% | +$1.09M |
|
34
Larimar Therapeutics
LRMR
$331M
| $6.22M | 0.21% |
+425,384
| New | +$6.22M |
|
35
VistaGen Therapeutics
VTGN
$112M
| $6.15M | 0.21% |
96,198
-53,334
| -36% | -$3.41M |
|
|
HARP
36
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $5.62M | 0.19% |
+26,860
| New | +$5.62M |
|
37
Shattuck Labs
STTK
$64.2M
| $5.57M | 0.19% |
190,330
+125,330
| +193% | +$3.67M |
|
38
Annovis Bio
ANVS
$44.8M
| $5.4M | 0.18% |
+193,368
| New | +$5.4M |
|
39
Synlogic
SYBX
$17M
| $5.34M | 0.18% |
+99,508
| New | +$5.34M |
|
|
SNCE
40
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $5.2M | 0.17% |
25,623
+373
| +1% | +$75.6K |
|
41
Alector
ALEC
$294M
| $5.19M | 0.17% |
257,500
+200,000
| +348% | +$4.03M |
|
42
Fulcrum Therapeutics
FULC
$367M
| $5.03M | 0.17% |
426,739
-10,961
| -3% | -$129K |
|
|
CLVS
43
DELISTED
Clovis Oncology, Inc.
CLVS
| $4.77M | 0.16% |
679,473
+37,365
| +6% | +$262K |
|
44
Aclaris Therapeutics
ACRS
$221M
| $4.74M | 0.16% |
188,200
-111,800
| -37% | -$2.82M |
|
|
ICAD
45
DELISTED
iCAD Inc
ICAD
| $4.62M | 0.16% |
217,637
+22,500
| +12% | +$477K |
|
46
Viking Therapeutics
VKTX
$2.97B
| $4.58M | 0.15% |
+724,754
| New | +$4.58M |
|
|
ODT
47
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $4.57M | 0.15% |
+1,336,412
| New | +$4.57M |
|
48
NextCure
NXTC
$13M
| $4.54M | 0.15% |
37,829
+21,162
| +127% | +$2.54M |
|
49
Ovid Therapeutics
OVID
$93.2M
| $4.52M | 0.15% |
+1,124,872
| New | +$4.52M |
|
|
CHAQ.U
50
DELISTED
Chardan Healthcare Acquisition 2 Corp. Units, each consisting of one share of Common Stock, and one
CHAQ.U
| $4.4M | 0.15% |
400,000
| – | – |
|